HER2/neu 癌基因的过度表达和/或扩增已被提议作为乳腺癌的预后标志物。相关肽 HER2 的检测仍然是癌症诊断和治疗决策中的巨大挑战。在这里，我们使用基于一维光子晶体 (1DPC) 激发的布洛赫表面波的生物传感装置作为标准技术的有效替代方案。 1DPC 经过优化，可在可见光谱下运行，生物传感器光学器件经过设计，可结合无标记和荧光操作模式。此功能可以使用与量子点缀合的检测单克隆抗体实时监测直接竞争测定，从而在荧光模式下准确区分 HER2 阳性/阴性人血浆样本。这种竞争性测定是使用图案化的交替区域来实施的，其中 HER2-Fc 嵌合体和参考分子进行生物缀合并以多重方式进行监测。通过结合无标记和荧光检测分析，我们能够调整检测参数，并在 20 分钟内提供人血浆中的 HER2 检测，从而实现经济有效的检测和快速周转时间。所提出的方法提供了一种有前途的技术，能够执行组合的无标记和荧光检测，用于疾病的诊断和治疗监测。版权所有 © 2023。由 Elsevier Inc. 出版。

The overexpression and/or amplification of the HER2/neu oncogene has been proposed as a prognostic marker in breast cancer. The detection of the related peptide HER2 remains a grand challenge in cancer diagnosis and for therapeutic decision-making. Here, we used a biosensing device based on Bloch Surface Waves excited on a one-dimensional photonic crystal (1DPC) as valid alternative to standard techniques. The 1DPC was optimized to operate in the visible spectrum and the biosensor optics has been designed to combine label-free and fluorescence operation modes. This feature enables a real-time monitoring of a direct competitive assay using detection mAbs conjugated with quantum dots for an accurate discrimination in fluorescence mode between HER2-positive/negative human plasma samples. Such a competitive assay was implemented using patterned alternating areas where HER2-Fc chimera and reference molecules were bio-conjugated and monitored in a multiplexed way. By combining Label-Free and fluorescence detection analysis, we were able to tune the parameters of the assay and provide an HER2 detection in human plasma in less than 20 min, allowing for a cost-effective assay and rapid turnaround time. The proposed approach offers a promising technique capable of performing combined label-free and fluorescence detection for both diagnosis and therapeutic monitoring of diseases.Copyright © 2023. Published by Elsevier Inc.